1	Ciba-Geigy	NNP	2	nn
2	Ltd.	NNP	6	nsubj
3	and	CC	2	cc
4	Chiron	NNP	5	nn
5	Corp.	NNP	2	conj
6	said	VBD	0	root
7	they	PRP	8	nsubj
8	extended	VBD	6	ccomp
9	their	PRP$	10	poss
10	offer	NN	8	dobj
11	for	IN	10	prep
12	Connaught	NNP	13	nn
13	BioSciences	NNP	14	nn
14	Inc.	NNP	11	pobj
15	,	,	10	punct
16	valued	VBN	10	partmod
17	at	IN	16	prep
18	866	CD	19	number
19	million	CD	21	num
20	Canadian	JJ	21	amod
21	dollars	NNS	17	pobj
22	-LRB-	-LRB-	23	punct
23	US$	$	21	dep
24	736	CD	23	number
25	million	CD	23	number
26	-RRB-	-RRB-	23	punct
27	to	TO	8	prep
28	Oct.	NNP	27	pobj
29	27	CD	28	num
30	.	.	6	punct

1	The	DT	2	det
2	companies	NNS	4	nsubj
3	earlier	RBR	4	advmod
4	said	VBD	0	root
5	they	PRP	8	nsubj
6	did	VBD	8	aux
7	n't	RB	8	neg
8	want	VB	4	ccomp
9	to	TO	10	aux
10	raise	VB	8	xcomp
11	their	PRP$	12	poss
12	offer	NN	10	dobj
13	to	TO	14	aux
14	match	VB	10	xcomp
15	a	DT	17	det
16	rival	JJ	17	amod
17	bid	NN	14	dobj
18	by	IN	17	prep
19	Institut	NNP	20	nn
20	Merieux	NNP	21	nn
21	S.A.	NNP	18	pobj
22	of	IN	17	prep
23	C$	$	22	pobj
24	37	CD	23	num
25	a	DT	26	det
26	share	NN	23	npadvmod
27	,	,	23	punct
28	or	CC	23	cc
29	C$	$	23	conj
30	942	CD	29	number
31	million	CD	29	number
32	.	.	4	punct

1	But	CC	3	cc
2	they	PRP	3	nsubj
3	said	VBD	0	root
4	the	DT	7	det
5	C$	$	7	amod
6	30-a-share	JJ	5	dep
7	bid	NN	19	nsubjpass
8	,	,	7	punct
9	which	WDT	11	nsubj
10	was	VBD	11	cop
11	due	JJ	7	rcmod
12	to	TO	13	aux
13	expire	VB	11	xcomp
14	Monday	NNP	13	tmod
15	,	,	7	punct
16	may	MD	19	aux
17	still	RB	19	advmod
18	be	VB	19	auxpass
19	extended	VBN	3	ccomp
20	or	CC	19	cc
21	varied	VBN	19	conj
22	.	.	3	punct

1	Merieux	NNP	13	nsubj
2	,	,	1	punct
3	a	DT	5	det
4	vaccine	NN	5	nn
5	manufacturer	NN	1	appos
6	based	VBN	5	partmod
7	in	IN	6	prep
8	Lyon	NNP	7	pobj
9	,	,	8	punct
10	France	NNP	8	appos
11	,	,	8	punct
12	is	VBZ	13	cop
13	51%-held	JJ	0	root
14	by	IN	13	prep
15	French	JJ	18	amod
16	state-owned	JJ	18	amod
17	Rhone-Poulenc	NNP	18	nn
18	S.A	NNP	14	pobj
19	.	.	13	punct

1	Ciba-Geigy	NNP	6	nsubj
2	is	VBZ	6	cop
3	a	DT	6	det
4	major	JJ	6	amod
5	pharmaceutical	JJ	6	amod
6	concern	NN	0	root
7	based	VBN	6	partmod
8	in	IN	7	prep
9	Basel	NNP	8	pobj
10	,	,	9	punct
11	Switzerland	NNP	9	appos
12	.	.	6	punct

1	Chiron	NNP	8	nsubjpass
2	,	,	1	punct
3	another	DT	5	det
4	pharmaceutical	JJ	5	amod
5	concern	NN	1	appos
6	,	,	1	punct
7	is	VBZ	8	auxpass
8	based	VBN	0	root
9	in	IN	8	prep
10	Emeryville	NNP	9	pobj
11	,	,	10	punct
12	Calif	NNP	10	appos
13	.	.	8	punct

1	Connaught	NNP	9	nsubj
2	is	VBZ	9	cop
3	a	DT	9	det
4	biotechnology	NN	5	nn
5	research	NN	9	nn
6	and	CC	5	cc
7	vaccine	NN	8	nn
8	manufacturing	NN	5	conj
9	concern	NN	0	root
10	.	.	9	punct

1	Institut	NNP	2	nn
2	Merieux	NNP	4	poss
3	's	POS	2	possessive
4	bid	NN	9	nsubj
5	for	IN	4	prep
6	Toronto-based	JJ	7	amod
7	Connaught	NNP	5	pobj
8	has	VBZ	9	aux
9	run	VBN	0	root
10	into	IN	9	prep
11	problems	NNS	10	pobj
12	with	IN	11	prep
13	the	DT	15	det
14	Canadian	JJ	15	amod
15	government	NN	12	pobj
16	,	,	15	punct
17	which	WDT	18	nsubj
18	told	VBD	15	rcmod
19	Merieux	NNP	18	dobj
20	last	JJ	21	amod
21	week	NN	18	tmod
22	that	IN	26	complm
23	it	PRP	26	nsubjpass
24	was	VBD	26	auxpass
25	n't	RB	26	neg
26	convinced	VBN	18	ccomp
27	that	IN	32	complm
28	the	DT	30	det
29	proposed	JJ	30	amod
30	acquisition	NN	32	nsubj
31	would	MD	32	aux
32	be	VB	26	ccomp
33	of	IN	32	prep
34	``	``	36	punct
35	net	JJ	36	amod
36	benefit	NN	33	pobj
37	''	''	36	punct
38	to	TO	36	prep
39	Canada	NNP	38	pobj
40	.	.	9	punct

1	Merieux	NNP	2	nn
2	officials	NNS	4	nsubjpass
3	are	VBP	4	auxpass
4	expected	VBN	0	root
5	to	TO	6	aux
6	meet	VB	4	xcomp
7	with	IN	6	prep
8	federal	JJ	9	amod
9	officials	NNS	7	pobj
10	in	IN	6	prep
11	Ottawa	NNP	10	pobj
12	today	NN	6	tmod
13	to	TO	14	aux
14	discuss	VB	6	xcomp
15	the	DT	16	det
16	decision	NN	14	dobj
17	.	.	4	punct


